rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Align Technology, Inc.

ALGN · Nasdaq

Health CareMedical DevicesNot moving yet

ALGN stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 12 weeks. It is 10.1% below that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 12
Industry in uptrend
29% -5 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.0M
Officials’ trades on record
56

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.

21 Apr – 20 Oct
19%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.9M$0$852KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

56 disclosed lines: House 43, Senate 5, executive 8; 16 people.

WhoDidAmountTraded
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k11 Sep 2025filed 23 Oct 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k11 Sep 2025filed 22 Oct 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k4 Aug 2025filed 12 Sep 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08sold$1k–$15k8 Apr 2025filed 8 May 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k26 Feb 2025filed 6 Mar 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08bought$1k–$15k25 Feb 2025filed 27 Mar 2025
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k20 May 2024filed 8 Jun 2024
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k27 Oct 2023filed 11 Nov 2023
Dan Sullivan Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k22 Aug 2023filed 22 Sep 2023
Dan Sullivan Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k22 Aug 2023filed 18 Sep 2023
Josh Gottheimer House: U.S. House ClerkNJ05boughtjoint$1k–$15k6 Mar 2023filed 20 Apr 2023
Josh Gottheimer House: U.S. House ClerkNJ05boughtjoint$1k–$15k27 Jan 2023filed 17 Feb 2023

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
John MoriciEVP, CHIEF FINANCIAL OFFICERsold7,969at $189.3118 Feb 2026filed 20 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Quentin S. Blackford Company insiderDirector · last 27 Aug 20260 · 0
Andrea Lynn Saia Company insiderDirector · last 20 May 20260 · 6
Anne Myong Company insiderDirector · last 20 May 20262 · 0
Britt J. Vitalone Company insiderDirector · last 20 May 20260 · 0
C. Raymond Larkin Jr. Company insiderDirector · last 20 May 20263 · 15
George J. Morrow Company insiderDirector · last 20 May 20261 · 7
Joseph Lacob Company insiderDirector · last 20 May 20260 · 35
Kevin J. Dallas Company insiderDirector · last 20 May 20261 · 0
Kevin T. Conroy Company insiderDirector · last 20 May 20260 · 0
Mojdeh Poul Company insiderDirector · last 20 May 20260 · 0
Susan E. Siegel Company insiderDirector · last 20 May 20260 · 3
John Morici Company insiderEVP, CHIEF FINANCIAL OFFICER · last 20 Feb 20261 · 10

Same industry

RCEL Avita MedicalLeading+108%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+52%
HAE HaemoneticsLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202567.2%
Operating profit marginFY 2025 · to 31 Dec 202513.5%
Free cash flow marginFY 2025 · to 31 Dec 202512.2%
Return on capital employedFY 2025 · to 31 Dec 202512.7%
Cash conversionFY 2025 · to 31 Dec 2025145%
Research spendFY 2025 · to 31 Dec 20259.2%
Share count trendFY 2025 · to 20 Feb 2026-0.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.1B
Free cash flowFY 2025 · to 31 Dec 2025$490.8M

Analyst forecasts

No analyst forecasts yet.